Drug Profile
MEDI 7510
Alternative Names: MEDI-7510; RSV sF+GLA-SELatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 07 Nov 2016 MedImmune terminates phase II trial in Respiratory syncytial virus infections (Prevention, In adults, In the elderly) in USA, Canada, Chile, Estonia, Latvia, Lithuania and South Africa.(NCT02508194)
- 28 Feb 2016 MedImmune completes a phase Ib trial for Respiratory syncytial virus infections (In the elderly, Prevention, In volunteers, In adults) in USA (NCT02289820)
- 06 Nov 2015 Phase-II clinical trials in Respiratory syncytial virus infections (In the elderly, Prevention, In volunteers, In adults) in Latvia (IM)